论文部分内容阅读
异环磷酰胺相对环磷酰胺有烷基化结构。早在70年代已用于临床试验。它经肝脏微粒体氧化酶系活化,临床上需采用大剂量治疗。在妇科肿瘤试验中异环磷酰胺在治疗卵巢上皮癌、宫颈鳞癌、滋养细胞疾病和未治的子宫肉瘤中都具有抗癌活性。异环磷酰胺和美斯纳(mesna)用于子宫内膜腺癌的Ⅱ期试验已着手进行。 研究对象均经病理证实为子宫内膜腺癌,52例接受手术和/或放疗后复发的晚期病人和对一线药
Ifosfamide relative to cyclophosphamide has an alkylated structure. As early as 70 years has been used in clinical trials. It is activated by the liver microsomal oxidase system, the need for high-dose clinical treatment. Ifosfamide in gynecologic oncology trials has anticancer activity in the treatment of epithelial ovarian cancer, cervical squamous cell carcinoma, trophoblastic disease and untreated uterine sarcoma. Phase II trials of ifosfamide and mesna for endometrial adenocarcinoma have already begun. Subjects were pathologically confirmed as endometrial adenocarcinoma, 52 patients undergoing surgery and / or radiotherapy recurrence of advanced patients and first-line drugs